key: cord-0991022-sizyxa0b
authors: Yıldırıcı, Şebnem; Yaylı, Savaş; Demirkesen, Cüyan; Vural, Seçil
title: New onset of pemphigus foliaceus following BNT162b2 vaccine
date: 2022-02-23
journal: Dermatol Ther
DOI: 10.1111/dth.15381
sha: 54911005442797cde1ff2b8e40c2503be74998ff
doc_id: 991022
cord_uid: sizyxa0b

nan

Dear Editor, A 65-year-old man was referred to the dermatology clinic with blisters. The lesions started one week ago as multiple lesions with scaling on his chest, back and scalp ( Figure 1 ). Oral mucosa was normal. One month ago, the patient had the BNT162b2 mRNA COVID-19 vaccine (Comirnaty, Biontech/Pfizer). He had hypertension for 10 years, and he has been using nebivolol 5 mg/day orally. A pill containing valsartan-hydrochlorothiazide combination was added to the treatment four months ago. Informed consent was obtained from the patient.

Lesional biopsy with hematoxylin-eosin stain showed intra- 

Covid-19 and autoimmunity

Aggressive course of pemphigus vulgaris following COVID-19 infection

Pemphigus vulgaris after COVID-19: a case of induced autoimmunity

Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination

Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2

Oral pemphigus after COVID-19 vaccination

Valsartan/hydrochlorothiazide induced pemphigus foliaceus